Targeting Tumor Associated Macrophages to Overcome Conventional Treatment Resistance in Glioblastoma.
crosstalks
glioblastoma
macrophages
microglia
radiation
resistance
tumor-associated macrophage
Journal
Frontiers in pharmacology
ISSN: 1663-9812
Titre abrégé: Front Pharmacol
Pays: Switzerland
ID NLM: 101548923
Informations de publication
Date de publication:
2020
2020
Historique:
received:
23
12
2019
accepted:
10
03
2020
entrez:
24
4
2020
pubmed:
24
4
2020
medline:
24
4
2020
Statut:
epublish
Résumé
Glioblastoma (GB) is the most common and devastating form of brain cancer. Despite conventional treatments, progression or recurrences are systematic. In recent years, immunotherapies have emerged as an effective treatment in a number of cancers, leaving the question of their usefulness also faced with the particular case of brain tumors. The challenge here is major not only because the brain is the seat of our consciousness but also because of its isolation by the blood-brain barrier and the presence of a unique microenvironment that constitutes the central nervous system (CNS) with very specific constituent or patrolling cells. Much of the microenvironment is made up of immune cells or inflammation. Among these, tumor-associated macrophages (TAMs) are of significant interest as they are often involved in facilitating tumor progression as well as the development of resistance to standard therapies. In this review, the ubiquity of TAMs in GB will be discussed while the specific case of microglia resident in the brain will be also emphasized. In addition, the roles of TAMs as accomplices in the progression of GB and resistance to treatment will be presented. Finally, clinical trials targeting TAMs as a means of treating cancer will be discussed.
Identifiants
pubmed: 32322199
doi: 10.3389/fphar.2020.00368
pmc: PMC7158850
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
368Informations de copyright
Copyright © 2020 Grégoire, Roncali, Rousseau, Chérel, Delneste, Jeannin, Hindré and Garcion.
Références
Mol Med Rep. 2016 Nov;14(5):4511-4520
pubmed: 27748891
Biomaterials. 2018 Apr;161:164-178
pubmed: 29421553
Clin Cancer Res. 2007 Dec 1;13(23):7119-25
pubmed: 18056192
Immunity. 2016 Mar 15;44(3):439-449
pubmed: 26982352
J Immunol. 2012 Jul 1;189(1):444-53
pubmed: 22664874
Neurosci Lett. 2017 Apr 3;645:106-112
pubmed: 28259657
Oncol Lett. 2018 Jan;15(1):285-291
pubmed: 29399139
Invest New Drugs. 2014 Dec;32(6):1278-84
pubmed: 24894651
Nat Commun. 2018 Feb 8;9(1):559
pubmed: 29422647
PLoS One. 2015 Feb 06;10(2):e0116644
pubmed: 25658639
Oncotarget. 2017 May 2;8(18):30576-30586
pubmed: 28427165
Int J Cancer. 2015 Oct 1;137(7):1630-42
pubmed: 25802036
Oncol Rep. 2016 Dec;36(6):3522-3528
pubmed: 27748906
J Pathol. 2008 Sep;216(1):15-24
pubmed: 18553315
Proc Natl Acad Sci U S A. 2016 Apr 19;113(16):4476-81
pubmed: 27044098
Mediators Inflamm. 2017;2017:9624760
pubmed: 28210073
J Neurooncol. 2017 Oct;135(1):37-46
pubmed: 28948499
Front Immunol. 2018 Jun 15;9:1329
pubmed: 29963047
Annu Rev Pathol. 2020 Jan 24;15:123-147
pubmed: 31530089
Biomaterials. 2017 Oct;142:1-12
pubmed: 28715655
Cell Mol Life Sci. 2015 Nov;72(21):4111-26
pubmed: 26210152
J Neurooncol. 2017 Jan;131(1):83-92
pubmed: 27664151
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Oncoimmunology. 2017 Nov 6;7(2):e1391973
pubmed: 29308321
Oncoimmunology. 2018 Jan 16;7(4):e1412909
pubmed: 29632728
Front Immunol. 2014 Oct 07;5:479
pubmed: 25339954
Cell Metab. 2019 Sep 3;30(3):493-507.e6
pubmed: 31257151
Sci Rep. 2016 Jul 14;6:29719
pubmed: 27411490
Oncoimmunology. 2013 Jan 1;2(1):e23033
pubmed: 23483678
Oncotarget. 2015 Jun 20;6(17):15077-94
pubmed: 25987130
Lancet Oncol. 2016 May;17(5):651-62
pubmed: 27055731
Int J Mol Sci. 2018 Jun 19;19(6):
pubmed: 29921749
Neuro Oncol. 2016 Jan;18(1):58-69
pubmed: 26433199
Glia. 2002 Nov;40(2):252-9
pubmed: 12379912
Front Oncol. 2018 Mar 12;8:49
pubmed: 29594035
PLoS One. 2015 May 15;10(5):e0126022
pubmed: 25978454
F1000Prime Rep. 2014 Mar 03;6:13
pubmed: 24669294
PLoS One. 2013 Aug 05;8(8):e69182
pubmed: 23940516
J Cancer. 2017 Jan 13;8(2):207-219
pubmed: 28243325
Nat Med. 2013 Nov;19(11):1423-37
pubmed: 24202395
Glia. 2011 Aug;59(8):1169-80
pubmed: 21446047
J Pathol. 2018 Sep;246(1):77-88
pubmed: 29888503
Cell Death Dis. 2019 Feb 27;10(3):199
pubmed: 30814491
Cancer Res. 2013 Nov 1;73(21):6413-23
pubmed: 24030977
Theranostics. 2017 Oct 12;7(18):4517-4536
pubmed: 29158842
Int J Cancer. 2015 Jul 15;137(2):278-88
pubmed: 25477239
Nat Cell Biol. 2015 Feb;17(2):170-82
pubmed: 25580734
Front Immunol. 2018 May 08;9:1004
pubmed: 29867979
World Neurosurg. 2018 Dec;120:e601-e610
pubmed: 30165233
Matrix Biol. 2013 Oct-Nov;32(7-8):372-80
pubmed: 23933178
J Exp Med. 2018 Mar 5;215(3):877-893
pubmed: 29436395
Sci Rep. 2017 Oct 23;7(1):13754
pubmed: 29062041
Acta Neuropathol. 2007 Aug;114(2):97-109
pubmed: 17618441
Neuro Oncol. 2006 Jul;8(3):261-79
pubmed: 16775224
FEBS J. 2018 Feb;285(4):680-699
pubmed: 29171156
Clin Adv Hematol Oncol. 2005 Nov;3(11):852-4
pubmed: 16491627
Stroke. 2012 Nov;43(11):3063-70
pubmed: 22933588
Neuro Oncol. 2013 Aug;15(8):1079-87
pubmed: 23828240
Front Cell Neurosci. 2018 Aug 03;12:235
pubmed: 30123112
Cell Stress. 2019 Jan 23;3(2):47-65
pubmed: 31225500
Oncotarget. 2015 Oct 20;6(32):33077-90
pubmed: 26427514
Lancet Oncol. 2009 May;10(5):459-66
pubmed: 19269895
Cancer Cell. 2017 Mar 13;31(3):326-341
pubmed: 28292436
J Neurooncol. 2010 Nov;100(2):177-86
pubmed: 20443131
Cancer Immunol Immunother. 2018 Oct;67(10):1491-1503
pubmed: 30030559
Nat Med. 2013 Oct;19(10):1264-72
pubmed: 24056773
Exp Oncol. 2010 Sep;32(3):186-9
pubmed: 21403615
Invest New Drugs. 2013 Jun;31(3):760-8
pubmed: 22907596
Oncoimmunology. 2013 Dec 1;2(12):e26968
pubmed: 24498562
Oncogene. 2017 Sep 21;36(38):5356-5368
pubmed: 28534507
Sci Rep. 2017 Jan 03;7:39011
pubmed: 28045028
Lancet Oncol. 2012 Jul;13(7):734-42
pubmed: 22704583
Cancer Res. 2018 Jun 1;78(11):3002-3013
pubmed: 29531161
Int J Mol Sci. 2018 Feb 01;19(2):
pubmed: 29389898
Clin Cancer Res. 2012 Dec 15;18(24):6748-57
pubmed: 22767669
Cell Rep. 2018 Sep 4;24(10):2561-2572.e6
pubmed: 30184491
J Biol Chem. 2013 Nov 1;288(44):31488-95
pubmed: 24045955
J Immunol. 2018 Jan 15;200(2):385-391
pubmed: 29311379
Front Oncol. 2018 Aug 13;8:314
pubmed: 30151353
Stem Cells. 2016 Aug;34(8):2026-39
pubmed: 27145382
Int J Cancer. 1999 Jul 2;82(1):12-6
pubmed: 10360813
Nat Commun. 2017 Jun 01;8:15080
pubmed: 28569747
Sci Rep. 2016 Jun 08;6:27548
pubmed: 27271009
Cancer Cell. 2013 Sep 9;24(3):331-46
pubmed: 23993863
Cancer Immunol Immunother. 2014 Aug;63(8):787-96
pubmed: 24770667
J Natl Cancer Inst. 2019 Mar 1;111(3):292-300
pubmed: 29947810
Cancer Res. 2016 Oct 1;76(19):5671-5682
pubmed: 27530322
Proc Natl Acad Sci U S A. 2019 Jan 15;116(3):997-1006
pubmed: 30602457
J Oncol. 2013;2013:486912
pubmed: 23737783
Cancer Chemother Pharmacol. 2013 Apr;71(4):1041-50
pubmed: 23385782
Target Oncol. 2015 Mar;10(1):111-23
pubmed: 24928772
J Clin Invest. 2016 Apr 1;126(4):1538-54
pubmed: 26999607
Oncotarget. 2017 Feb 14;8(7):12145-12157
pubmed: 28076333
J Neuroinflammation. 2017 Nov 13;14(1):220
pubmed: 29132376
Int J Cancer. 2015 Aug 15;137(4):826-36
pubmed: 25604093
Cancer Immunol Res. 2018 Oct;6(10):1220-1233
pubmed: 30131377
Front Oncol. 2018 Nov 08;8:503
pubmed: 30467536
Front Cell Neurosci. 2013 Apr 17;7:45
pubmed: 23616747
Acta Neuropathol. 1987;74(3):269-77
pubmed: 3314311
Neuro Oncol. 2015 Jul;17(7):978-91
pubmed: 25537019
PLoS One. 2016 Apr 19;11(4):e0153550
pubmed: 27092773
Immunity. 2014 Jul 17;41(1):14-20
pubmed: 25035950
Pharmacol Ther. 2016 Feb;158:24-40
pubmed: 26617219
J Biol Chem. 2018 Apr 13;293(15):5509-5521
pubmed: 29463677
Mod Pathol. 2016 Mar;29(3):212-26
pubmed: 26769142
J Neurosurg. 2018 Apr;128(4):1091-1101
pubmed: 28574310
PLoS One. 2012;7(12):e50946
pubmed: 23284651
J Control Release. 2017 Dec 28;268:128-146
pubmed: 29051064
Neoplasia. 2017 Jan;19(1):1-7
pubmed: 27940247
Neuro Oncol. 2016 Apr;18(4):557-64
pubmed: 26449250
J Exp Med. 2018 Mar 5;215(3):859-876
pubmed: 29436396
PLoS One. 2017 Jun 30;12(6):e0179012
pubmed: 28666020
Neuropathol Appl Neurobiol. 2018 Feb;44(2):185-206
pubmed: 28767130
Neuro Oncol. 2015 May;17(5):685-96
pubmed: 25378632
Sci Transl Med. 2017 Mar 15;9(381):
pubmed: 28298418
AJNR Am J Neuroradiol. 2018 Feb;39(2):252-259
pubmed: 29191871
N Engl J Med. 2015 Jul 30;373(5):428-37
pubmed: 26222558
Cancers (Basel). 2018 Dec 20;11(1):
pubmed: 30577488
Am J Pathol. 2017 Sep;187(9):2080-2094
pubmed: 28734730
Exp Neurol. 2000 Apr;162(2):290-6
pubmed: 10739635
Oncotarget. 2018 Nov 2;9(86):35655-35665
pubmed: 30479695
EBioMedicine. 2018 Apr;30:94-104
pubmed: 29559295
Hum Mol Genet. 2018 Aug 1;27(R2):R187-R194
pubmed: 29668946
Br J Cancer. 2018 Nov;119(10):1171-1181
pubmed: 30393372
Cancer Cell. 2017 Aug 14;32(2):253-267.e5
pubmed: 28810147
Neuro Oncol. 2016 Feb;18(2):206-15
pubmed: 26180083
Oncotarget. 2018 May 4;9(34):23532-23542
pubmed: 29805753
Nat Neurosci. 2016 Jan;19(1):20-7
pubmed: 26713745
Glia. 2018 Jan;66(1):161-174
pubmed: 28948650
Immunity. 2014 Jul 17;41(1):49-61
pubmed: 25035953
Neuro Oncol. 2018 Jan 10;20(1):92-102
pubmed: 28605477
Tumour Biol. 2017 May;39(5):1010428317699797
pubmed: 28459367
Clin Cancer Res. 1999 May;5(5):1107-13
pubmed: 10353745
Nat Commun. 2019 May 22;10(1):2272
pubmed: 31118418
Nature. 2013 Apr 25;496(7446):445-55
pubmed: 23619691
Nat Immunol. 2010 Oct;11(10):889-96
pubmed: 20856220
Cancer Chemother Pharmacol. 2015 Apr;75(4):701-9
pubmed: 25627002
Acta Neuropathol. 2016 Jun;131(6):803-20
pubmed: 27157931
Oncogene. 2017 Oct 26;36(43):6049-6058
pubmed: 28759044
Nat Neurosci. 2018 Sep;21(9):1209-1217
pubmed: 30150661
Oncotarget. 2017 Aug 7;8(42):72597-72612
pubmed: 29069812
Brain. 2017 Jun 1;140(6):1548-1560
pubmed: 28334886
Cancer Res. 2017 May 1;77(9):2266-2278
pubmed: 28235764
Brain Pathol. 2019 Jul;29(4):513-529
pubmed: 30506802
Neuro Oncol. 2016 Aug;18(8):1120-8
pubmed: 26917236
JCI Insight. 2019 Feb 21;4(4):
pubmed: 30830865
Ann Oncol. 2015 Dec;26(12):2483-90
pubmed: 26386124
N Engl J Med. 2005 Mar 10;352(10):987-96
pubmed: 15758009
Stem Cell Reports. 2015 Apr 14;4(4):531-40
pubmed: 25754205
Proc Natl Acad Sci U S A. 2015 Nov 10;112(45):E6215-23
pubmed: 26512116
Cancer Res. 2012 Aug 15;72(16):4119-29
pubmed: 22693253